a Chongqing Research Center for Pharmaceutical Engineering , Chongqing Medical University , Chongqing , China.
b Chongqing Key Laboratory of Molecular Oncology and Epigenetics , the First Affiliated Hospital of Chongqing Medical University , Chongqing , China.
Expert Opin Drug Metab Toxicol. 2018 Sep;14(9):951-960. doi: 10.1080/17425255.2018.1505863. Epub 2018 Aug 6.
Anticancer enzymes play important roles in cancer treatment. The anticancer enzyme has been in clinical use to treat acute lymphoblastic leukemia for many years. Other types of anticancer enzymes have been investigated in laboratory studies and clinical trials. Area covered: This paper will provide perspectives on the indications, anticancer mechanisms, enzymatic characteristics (such as molecular weight, organism source, and kinetic parameters) and pharmacokinetic behaviors of anticancer enzymes and their delivery systems by systematically analyzing available literature. The pharmacodynamics of anticancer enzyme delivery systems has also been summarized. Expert opinion: Anticancer enzymes kill cancer cells by depleting important nutrients required for growth or producing metabolite toxic to tumor cells. Suitable enzyme delivery systems have demonstrated promising effects on the pharmacokinetics, bioactivity and application of anticancer enzymes. Their current limitations and future potential are analyzed.[Figure: see text].
抗癌酶在癌症治疗中发挥着重要作用。抗癌酶已在临床上用于治疗急性淋巴细胞白血病多年。其他类型的抗癌酶已在实验室研究和临床试验中进行了研究。
本文将通过系统分析现有文献,提供抗癌酶及其递药系统的适应证、抗癌机制、酶学特性(如分子量、生物来源和动力学参数)和药代动力学行为的观点。还总结了抗癌酶递药系统的药效学。
抗癌酶通过耗尽生长所需的重要营养物质或产生对肿瘤细胞有毒的代谢物来杀死癌细胞。合适的酶递药系统已证明对抗癌酶的药代动力学、生物活性和应用具有有前景的效果。分析了它们目前的局限性和未来的潜力。[图:见正文]。